MK-677 (Ibutamoren) — Indexed Studies

LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report.

Cardaci TD, Machek SB, Wilburn DT et al.

A GH Secretagogue Receptor Agonist (LUM-201) Elicits Greater GH Responses than Standard GH Secretagogues in Subjects of a Pediatric GH Deficiency Trial.

Bright GM, Thorner MO

Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study.

Campbell GA, Patrie JT, Gaylinn BD et al.

MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study.

Adunsky A, Chandler J, Heyden N et al.

Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.

Sevigny JJ, Ryan JM, van Dyck CH et al.

Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.

Nass R, Pezzoli SS, Oliveri MC et al.

Summaries for patients. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults.

Impurity profile tracking for active pharmaceutical ingredients: case reports.

Zhou L, Mao B, Reamer R et al.

The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture.

Bach MA, Rockwood K, Zetterberg C et al.

The effect of treatment with the oral growth hormone (GH) secretagogue MK-677 on GH isoforms.

Svensson J, Boguszewski CL, Shibata F et al.

Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.

Codner E, Cassorla F, Tiulpakov AN et al.

Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.

Murphy MG, Weiss S, McClung M et al.

Growth hormone secretagogues: mechanism of action and use in aging.

Fuh VL, Bach MA

Endocrine and non-endocrine activities of growth hormone secretagogues in humans.

Ghigo E, Arvat E, Broglio F et al.

Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677.

Svensson J, Carlsson B, Carlsson LM et al.

Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.

Murphy MG, Bach MA, Plotkin D et al.

Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a).

Svensson J, Jansson JO, Ottosson M et al.

Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.

Svensson J, Ohlsson C, Jansson JO et al.

Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.

Svensson J, Lönn L, Jansson JO et al.

MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.

Murphy MG, Plunkett LM, Gertz BJ et al.

Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man.

Copinschi G, Leproult R, Van Onderbergen A et al.

Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.

Chapman IM, Pescovitz OH, Murphy G et al.

Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.

Chapman IM, Bach MA, Van Cauter E et al.

Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men.

Copinschi G, Van Onderbergen A, L'Hermite-Balériaux M et al.

Acute stress suppresses hunger-driven food seeking through PVN activation: Reversal by anxiolytic drug and ghrelin receptor agonist, with anxiolytic-like effects of refeeding.

Tojo R, Tashiro M, Takahashi H et al.

Knowing the minimal detectable dose can facilitate the interpretation of a hair test result: II. Case example with ibutamoren (MK-677), a growth hormone secretagogue.

Kintz P, Gheddar L

Hepatotoxicity induced by MK-677.

Cobani E, Amin MS, Hasso M et al.

SARMs, Metabolic Modulators and Growth Hormone Secretagogues in Suspected Illegal Medicines, Bought as Sport Performance Enhancers: A Retro- and Prospective Study Within the GEON.

Barrios MM, Deconinck E, Vanhee C et al.

Design, Biological Characterization, and Discovery of Capromorelin Derivatives as Oral Growth Hormone Secretagogue Receptor Type 1a Agonist for the Treatment of Growth Hormone Deficiency.

Xu H, Liu M, Jia X et al.

Investigating the P53-dependent anti-cancer effect of ibutamoren in human cancer cell lines.

Abdul Ghafoor N, Rasuli S, Tanriverdi Ö et al.

Reversible Gynecomastia and Hypogonadism Due to Usage of Commercial Performance-Enhancing Supplement Use.

Chong S, Woolnough CA, Koyyalamudi SR et al.

Detection of the growth hormone secretagogue MK-0677 in equine hair following oral administration.

Viljanto M, Cutler C, Taylor P et al.

Characterization of growth hormone secretagogue small molecule ibutamoren (MK-0677) and its possible metabolites in thoroughbred horses for doping control.

Philip M, Karakka Kal AK, Subhahar MB et al.

Equine metabolism of the growth hormone secretagogue MK-0677 in vitro and in urine and plasma following oral administration.

Cutler C, Viljanto M, Taylor P et al.

Neural networks for computing and denoising the continuous nonlinear Fourier spectrum in focusing nonlinear Schrödinger equation.

Sedov EV, Freire PJ, Seredin VV et al.

Development and validation of SARMs and metabolic modulators screening in hair using UHPLC-MS/MS: Application to a doping case and first identification of S23 in authentic human hair.

Gheddar L, Raul JS, Kintz P

Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren.

Liu H, Sun D, Myasnikov A et al.

Characterization of equine liver microsome-generated metabolites of growth hormone secretagogue small molecule ibutamoren.

Philip M, Karakka Kal AK, Subhahar MB et al.

Role of Satb1 and Satb2 Transcription Factors in the Glutamate Receptors Expression and Ca(2+) Signaling in the Cortical Neurons In Vitro.

Turovsky EA, Turovskaya MV, Fedotova EI et al.

Skin Acceleration Levels Estimated by a Neck-surface Accelerometer during Phonation Are Affected by The Mechanical Properties of The Anterior Cervical Skin.

Umatani M, Ogawa M, Hosokawa K et al.

Development and validation of liquid chromatography-tandem mass spectrometry method for screening six selective androgen receptor modulators in dietary supplements.

Lee JH, Han JH, Jung EJ et al.

An in vitro assay approach to investigate the potential impact of different doping agents on the steroid profile.

Piper T, Heimbach S, Adamczewski M et al.

Brain and kidney GHS-R1a underexpression is associated with changes in renal function and hemodynamics during neurogenic hypertension.

Sales da Silva E, Ferreira PM, Castro CH et al.

Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles.

Yoon YS, Jang Y, Hoenen T et al.

MK0677, a Ghrelin Mimetic, Improves Neurogenesis but Fails to Prevent Hippocampal Lesions in a Mouse Model of Alzheimer's Disease Pathology.

Tian J, Wang T, Wang Q et al.

Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats.

Lee J, Kwon A, Chae HW et al.

MK-0677, a Ghrelin Agonist, Alleviates Amyloid Beta-Related Pathology in 5XFAD Mice, an Animal Model of Alzheimer's Disease.

Jeong YO, Shin SJ, Park JY et al.

Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet.

Van Wagoner RM, Eichner A, Bhasin S et al.

Central Ghrelin Resistance Permits the Overconsolidation of Fear Memory.

Harmatz ES, Stone L, Lim SH et al.

Thyroid hormone modulates food intake and glycemia via ghrelin secretion in Zucker fatty rats.

Patel K, Joharapurkar A, Dhanesha N et al.